Forbion European Acquisition Corp.

Forbion European Acquisition Corp. (Nasdaq: FRBN) is a blank-check company sponsored by Forbion, a European life sciences-focused investment firm with deep roots in biotechnology and healthcare venture investing. The SPAC completed its initial public offering in 2021, targeting acquisition opportunities in the European life sciences and healthcare sector. On October 2, 2023, the company filed a Definitive Proxy Statement on Schedule DEFM14A with the SEC, signaling that shareholders were being asked to vote on a proposed business combination. The filing reflects an active deal process as the vehicle seeks to complete its merger. Visit SpacDesk and sign up for full access to FRBN's filing history, timeline data, and deal analytics.